CPC Patent Technologies v. Apple: Supreme Court Denies Cert in 45 Days
Australian patent assertion entity CPC Patent Technologies sought U.S. Supreme Court review of its infringement claims against Apple over two patents covering biometric remote-entry and body-canal fluid-control technologies. The Court denied the petition without merits review, closing the matter in just 45 days.
Supreme Court slams the door on CPC’s Apple patent challenge
CPC Patent Technologies Pty. Ltd., an Australian patent holding entity represented by K&L Gates, filed a petition for writ of certiorari at the U.S. Supreme Court on 26 September 2025, seeking review of lower-court rulings in its infringement dispute against Apple, Inc. The patents at issue — US9655705B1 and US9269208B2 — broadly cover a remote entry system with biometric authentication components and body-canal-contacting means for fluid-flow control, technology domains relevant to Apple’s device access and health-monitoring product lines.
The Supreme Court denied the petition on 10 November 2025, terminating the case in just 45 days. A cert denial is not a ruling on the merits; the Court exercises near-total discretion over its docket and typically accepts fewer than 2% of petitions filed. The denial leaves the decision of the court below — adverse to CPC — undisturbed. Apple, represented by Morrison & Foerster, achieves finality without further litigation risk at the federal appellate apex.
The 45-day resolution is notably swift and consistent with petitions the Court disposes of early in conference without requesting a response from the opposing party. The public record does not reveal whether Apple was invited to respond or whether the petition was relisted. What drove CPC to seek Supreme Court review — whether a circuit split, a constitutional question, or a novel claim-construction issue — remains undisclosed from the docket, limiting external analysis of the petition’s substantive theory.
Filing to Petition Dismissed in 45 days
45 days from filing to denial — well below the median cert petition lifespan of ~150 days
Cert denied: what the Supreme Court’s refusal means for both parties
Cert denial ends the road — no merits ruling issued
A denial of certiorari is a procedural disposition: the Supreme Court declines to exercise jurisdiction and issues no opinion on the underlying patent claims. Under long-standing Court practice, a cert denial carries no precedential weight and does not imply agreement or disagreement with the lower court’s reasoning. It simply means fewer than four Justices voted to hear the case, making the lower-court judgment final and binding on the parties.
Procedural — no merits decidedCPC exhausts federal options; patents remain unenforced against Apple
For CPC Patent Technologies, the denial forecloses any further U.S. federal judicial avenue against Apple on this litigation track. The patents themselves are not invalidated by this outcome, so CPC could theoretically assert them against other defendants. However, the adverse lower-court record — now final — may create estoppel or persuasive-authority risks in future proceedings involving the same claims and substantially similar accused products.
CPC’s enforcement bid closedApple secures finality on biometric remote-entry patent claims
Apple achieves a clean litigation exit without any Supreme Court merits exposure. The denial cements the lower-court outcome in Apple’s favour and eliminates ongoing legal uncertainty over US9655705B1 and US9269208B2 as they relate to Apple’s products. Morrison & Foerster’s strategy — whether to oppose or waive response — contributed to a swift 45-day closure, a commercially valuable outcome given Apple’s high-volume product development calendar.
Apple: full finality achievedBiometric access IP assertions face a high bar at the Supreme Court
This denial is consistent with the Court’s historical reluctance to review patent infringement disputes absent a clear circuit split or constitutional question. For patent assertion entities targeting consumer-electronics biometric systems, the case suggests that building a Supreme Court-worthy petition requires more than adverse lower-court rulings — a compelling federal question must be squarely presented. Apple’s IP litigation posture in biometric access technology remains robust.
PAE enforcement risk: reducedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | CPC Patent Technologies Pty. Ltd. | Company | Australian patent holding entity — asserting US9655705B1 and US9269208B2 against AppleSearch in Eureka ↗ |
| Defendant | Apple, Inc. | Company | Apple, Inc. — consumer electronics and software platform maker defending biometric IP claimsSearch in Eureka ↗ |
| Plaintiff counsel | George Clark Summerfield | Attorney | Counsel for CPC Patent Technologies Pty. Ltd.Search in Eureka ↗ |
| Plaintiff law firm | K&L Gates, LLP | Law Firm | Representing CPC Patent Technologies Pty. Ltd.Search in Eureka ↗ |
| Defendant counsel | Brian Robert Matsui | Attorney | Counsel for Apple, Inc.Search in Eureka ↗ |
| Defendant law firm | Morrison & Foerster, LLP | Law Firm | Representing Apple, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | U.S. Supreme CourtSearch in Eureka ↗ |
Official order — verbatim text
The terse ‘Petition DENIED’ disposition is the Supreme Court’s standard one-line order and carries no explanatory reasoning. It confirms only that fewer than four Justices voted to grant review under the Rule of Four. No merits analysis of US9655705B1 or US9269208B2 was conducted. The lower-court judgment adverse to CPC therefore stands as final, and neither the validity nor the scope of the asserted claims was adjudicated at this level. Practitioners should note that this outcome cannot be cited as Supreme Court authority on the substantive patent questions.
US9655705B1 & US9269208B2 — biometric remote entry and body-canal fluid-control
US9655705B1 (App. No. 14/837113) claims a remote entry system incorporating biometric authentication — technology directly relevant to smartphone and wearable device unlock mechanisms. US9269208B2 (App. No. 13/572166) claims body-canal contacting means for controlling body fluid flow, a specification with potential application in medical sensors, smart catheters, and wearable health monitors. Both patents are granted US utility patents assigned to CPC Patent Technologies Pty. Ltd., an Australian entity with a history of cross-market assertion.
The strategic significance of these patents lies in their breadth across two converging markets: consumer biometric security (dominated by Apple’s Face ID and Touch ID ecosystem) and wearable health sensing (a battlefield for Apple Watch, continuous glucose monitors, and next-generation health wearables). CPC’s willingness to escalate to the Supreme Court signals confidence in claim scope, and the patents’ survival of this litigation without invalidation preserves their enforcement utility against any market entrant in these spaces.
Should your team run an FTO against US9655705B1 and US9269208B2?
Any company developing biometric device-access systems, remote-entry authentication hardware, or body-worn fluid-sensing devices should assess exposure to CPC’s portfolio. The cert denial means these patents are fully enforceable and have survived a full litigation cycle. Product teams launching wearable health monitors, smart-lock systems, or hospital-grade fluid-management devices are squarely within the potential claim scope suggested by the patent titles and application histories.
PatSnap Eureka’s FTO Search Agent can map your product’s feature set against the independent claims of US9655705B1 and US9269208B2, identify prior art that may support IPR petitions, and surface related CPC portfolio patents that could expand assertion risk. Run a claim-chart analysis before your next product launch to quantify exposure and design-around options before CPC identifies your product as its next target.
Run a freedom-to-operate analysis on US9655705B1 to assess your product’s exposure
Run FTO in Eureka →Similar biometric and remote-entry patent cases at the Supreme Court
Cases involving biometric access and wearable health-sensor patents petitioned to the U.S. Supreme Court, including other PAE-driven cert petitions against major consumer electronics defendants.
What this case signals for the biometric access IP landscape
The swift cert denial reinforces Apple’s defensive posture and signals diminishing returns for PAE-driven biometric patent assertions at the apex court.
Cert denial does not kill the patents — watch for new defendants
US9655705B1 and US9269208B2 survive this proceeding. CPC may redirect enforcement efforts toward other consumer-electronics or healthcare-device companies with accused biometric or fluid-monitoring products. Competitors operating in adjacent technology spaces should treat these patents as live threats and conduct proactive FTO analysis.
Swift 45-day denial suggests weak jurisdictional hook, not just weak facts
When the Supreme Court denies cert this quickly, it typically signals the petition lacked a compelling federal question — a circuit split, constitutional issue, or statutory interpretation conflict — rather than merely a losing factual record. Patent litigators structuring future high-stakes appeals should front-load the jurisdictional hook to avoid early-conference denial.
CPC v Apple — key questions answered
The cert denial means the Supreme Court declined to review the lower-court ruling without addressing the merits of the patent infringement claims. Fewer than four Justices voted to hear the case. The denial is not a ruling on whether US9655705B1 or US9269208B2 were infringed or valid — it simply makes the adverse lower-court judgment against CPC final and unappealable in the federal system.
Yes. A cert denial does not invalidate the patents. US9655705B1 and US9269208B2 remain granted U.S. patents. CPC Patent Technologies retains the right to assert them against other defendants. However, the adverse lower-court record on infringement — now final against Apple — could carry persuasive weight in future proceedings involving substantially similar accused products or claim constructions.
The 45-day resolution is consistent with the Court disposing of petitions at an early conference, often without requesting a response from the opposing party. This typically occurs when the petition lacks a compelling federal question — such as a circuit split, constitutional issue, or major statutory ambiguity — regardless of the strength of the underlying patent claims. The precise reason is not stated in the Court’s order.
Based on the patent titles, US9655705B1 covers remote entry systems with biometric authentication, suggesting relevance to Apple’s Touch ID, Face ID, and device-unlock ecosystem. US9269208B2 covers body-canal fluid-flow control devices, suggesting potential relevance to Apple Watch health sensors or other body-contact monitoring hardware. The specific accused products are not identified in the Supreme Court docket as publicly available.
Yes. The litigation outcome binds only the parties — CPC and Apple. The patents remain in force and CPC is not legally precluded from asserting them against other defendants in new actions. Companies in the biometric access, smart-lock, or wearable health-monitoring sectors should be aware that these patents survived a complete litigation cycle and are potentially available for future enforcement campaigns by CPC.
PatSnap Eureka searches patents and litigation data to answer instantly.